Implemented in 2006, Medicare prescription drug benefit (Part D) spent $65.8 billion for prescription drugs in 2011, according to the Congressional Budget Office. But Medicare beneficiaries are overpaying by hundreds of dollars annually because of difficulties selecting the ideal prescription drug plan for their medical needs, an investigation by the University of Pittsburgh Graduate School of Public Health reveals. Their work also could be useful in designing health insurance exchanges, which are state-regulated organizations created under the Affordable Care Act ("Obamacare") to offer standardized health care plans.
Only 5.2 percent of beneficiaries chose the least-expensive Medicare prescription drug benefit (Part D) plan that satisfied their medical needs in 2009, overspending on Part D premiums and prescription drugs by an average of $368 each per year. The evaluation took a national look at how well beneficiaries were making plan choices in the fourth year of the Medicare Part D program and could help guide changes to health insurance programs.
Their solution, unfortunately, is even more government employees to counsel recipients, which may cost a lot more than $368 per year.
"In particular, government officials could recommend the three most appropriate Part D plans for each person, based on their medication history," said co-author Yuting Zhang, Ph.D., associate professor of health economics at Pitt Public Health. "Alternatively, they could assign beneficiaries to the best plan for them based on their medication needs, while offering them the option to choose another plan instead. In designing health insurance exchanges, models with more active assistance would be more helpful than models with large numbers of plans and information. For example, health insurance exchanges could actively screen plans on quality and negotiate premiums to reduce the number of plans."
The researchers looked at the difference in a patient's total spending, including the plan premium and out-of-pocket payment for the prescriptions filled, between the plan the patient chose and the cheapest alternative option in the region that would satisfy the patient's medication needs. The study looked at data for 412,712 people, with an average age of 75.
Beneficiaries tend to overprotect themselves by purchasing plans with more generous features, such as generic drug coverage in the coverage gap.
A few other trends emerged: As beneficiaries aged, they increasingly chose more expensive plans, with people older than 85 overspending by $30 more than people 65 to 69 years old. Blacks, Hispanics and Native Americans chose less expensive plans than whites.
People with common medical conditions, such as diabetes and chronic heart failure, were not significantly more likely to choose more expensive plans. People with cognitive deficits or mental health issues, such as Alzheimer's disease, tended to choose less expensive plans, spending an average of $10 less than those without such conditions. The researchers could not determine if those people had assistance from caregivers.
As the number of plan options increased in a region, the amount of overspending increased by $3.20 for every additional plan available.
"A previous study showed that in 2006, beneficiaries could have saved nearly 31 percent of their total drug spending by switching to the lowest cost plan," said lead author Chao Zhou, Ph.D., a post-doctoral associate at Pitt Public Health. "Since our results are similar, this suggests people are not learning to reduce overspending."
One possible explanation for these consistent results over time is the impact of inertia and bias toward maintaining the status quo, she noted.
"When Medicare Part D started in 2006, the majority of beneficiaries did not choose the least expensive plan," said Zhou. "Over time, they may have simply stuck to their original plan and never switched to a better one. Beneficiaries might not spend much time researching and adjusting their plan choices based on changes in their medication needs and in plan options."
Findings from the private health insurance market support the authors' conclusion that people keep their current plan instead of spending time researching and optimizing their plan choices based on their insurance use and prescription spending in the previous year.
Published in Health Affairs
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Schrödinger's Cat Is Not Just Alive And Dead, He's Both In 2 Places At Once
- Case For Moon: Humanity's Gateway To The Solar System - Open Ended Exploration With Planetary Protection At Its Heart
- Mindfulness Is Not A Waste Of Time
- B0 Meson Lifetime Difference Measured By ATLAS
- Arctic Ocean Methane Does Not Reach The Atmosphere
- Voluntary Birth Control To Stop Climate Change - Or Else
- Italian Food Scientists Are Tired Of Phony Cheese
- "this must be mystery, Cat Mystery. lol..."
- "Vampire are not real, and can never be. This stuff is limited to movies only...."
- "Milk is so tasty. Soy, Oy! CO2 is fertilizer for plants. We need more of it. Meat is tasty too..."
- "Both the Pacific Salmon Forum and the Cohen Commission agree there is scant evidence farming salmon..."
- "If interested in an electromagnetic model of the photon structure and its absorption process, as..."
- The Name Game: How Unethical Environmental Groups and Toxic Fanatics Scare You With Words
- Naturopathy: A Pre-holiday Rant
- Misdiagnosis of Dehydration in Older Folks
- The Amazing Things Poo Can Tell Us About Health
- This Dinner Plate Sucks—Literally
- Gwynn’s Appeal to Jury Could Overshadow Medical Science
- New meta-analysis shows ketamine effective against persistent post-surgical pain and could provide major cost-savings globally
- Refusing access to surgery recovery area at a UK hospital unless WHO Safe Surgery Checklist is fully complete
- Investment in energy storage vital if renewables to achieve full potential
- The Lancet Oncology: Teenagers and young adults still fare worse than children for many common cancers, according to Europe-wide
- Coping with active surveillance anxiety in prostate cancer